Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
STOUGHTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2024 financial results after the market closes on Thursday, August 8, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-report-second-quarter-2024-financial-results-august-8
From BIOWORLD -
Infection
Enanta Pharmaceuticals describes new PL-pro
July 22, 2024
Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections. [Subscription needed]
https://www.bioworld.com/articles/710689-enanta-pharmaceuticals-describes-new-pl-pro?v=preview
FWIW -
Friday, July 19, 2024 - A possible WIN for ENTA?
Reply to Response to Motion Fri 07/19 4:10 PM
SEALED REPLY in Support of 296 MOTION to Compel Defendant Pfizer Inc. to Produce Documents and Provide Deposition Testimony filed by Enanta Pharmaceuticals, Inc..(Cook, Savannah)
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
What has peeked my interest is the after-market trading. Approximately 2 weeks ago, I started accumulating shares en masse due to the fact that 100K- 300K+ additional shares were being traded in the after hours. Not sure if this has anything to do with the uptrend. However, psychologically - remember approximately 3 years ago the stock was $100+ PPS. Something very positive is happening - legal, clinical trials, M & A (with the new attorney on board) & the FLO Foundation is riding the wave!
https://www.nasdaq.com/market-activity/stocks/enta/after-hours
IMHO - all these patents would be a significant value incentive for a merger or a buyout -
As of June 25, 2024 -
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Type: Grant
Filed: December 2, 2022
Date of Patent: June 25, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
https://patents.justia.com/patent/12018017
A series of studies using ASK1-deficient mice have indicated that ASK1 plays important roles in many stress-related diseases, including cardiovascular and neurodegenerative diseases, suggesting that small compounds that inhibit ASK1 activity could possibly be used for the amelioration of the development and/or progression of these diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491083/
O/T ----
We need some LEVITY here. One of my favorite movie scenes.
Might as well continue to list patents as they are granted. Who know what leverage they'll have in a potential acquisition or merger?
Hepatitis B antiviral agents
Patent number: 12011425
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: January 25, 2023
Date of Patent: June 18, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Yao-Ling Qiu, Xuri Gao, Jorden Kass, Hui Cao, Wei Li, Xiaowen Peng, Byung-Chul Suh, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
FWIW - Addendum - Barbara Fiacco - ENTA, if only -
Represented Dana-Farber as lead counsel in second case against Bristol-Myers Squibb and Ono Pharmaceuticals, asserting claims for unjust enrichment and unfair competition for depriving Dana-Farber of its co-ownership rights under eight patents directed to cancer immunotherapy. On the eve of trial, in the face of Dana-Farber’s claim for hundreds of millions of dollars in damages, Defendants settled, making a substantial lump sum payment to Dana-Farber and agreeing to make potential additional payments, contingent on future events.
https://foleyhoag.com/people/fiacco-barbara/#Experience
ENTA has an outstanding litigator in their representation - Barbara Fiacco
Quote - The following Foley Hoag partners were also recognized for excellence in the industry in the following jurisdictions, and were described by IAM as:
Barbara Fiacco (National) and Donald Ware (MA) ranked in the Gold tier for litigation.
“Two of the most high-quality trial lawyers Boston has to offer,” and “A formidable team in life sciences litigation, securing multiple victories for the Dana-Farber Cancer Institute, resulting in significant payouts as well as co-ownership of groundbreaking cancer treatment patents.”
https://foleyhoag.com/news-and-insights/news/2024/june/foley-hoag-10-partners-recognized-in-2024-edition-of-iam-patent-1000/
https://foleyhoag.com/people/fiacco-barbara/
Here's the latest. Appears that ENTA is progressing well as of June 13. Comments?
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
June 13, 2024
STOUGHTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of U.S. exclusivity from June 27, 2025, to July 3, 2026. FDA’s grant of pediatric exclusivity now extends exclusivity of the Nucynta Franchise an additional six months, to January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER.
“We are pleased with FDA’s grant of pediatric exclusivity for the Nucynta Franchise,” said Thomas Smith, M.D., Collegium’s Chief Medical Officer. “This grant of pediatric exclusivity enhances the value of the Nucynta franchise and bolsters our near-term outlook. Collegium is proud to lead with science in support of people living with serious medical conditions and the communities we serve.”
Nucynta is currently approved in the U.S. for the management of acute pain severe enough to require an opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative treatments are inadequate in adults and pediatric patients aged six years and older with a body weight of at least 40 kg.
Nucynta ER is currently approved in the U.S. for the management of severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative treatment options are inadequate, and severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-obtains-six-month-extension-us-pediatric-exclusivity
Two more for the books -
Patent number: 12006291
Abstract: The present invention relates to processes for preparing a Compound (1): or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.
Type: Grant
Filed: January 10, 2023
Date of Patent: June 11, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Kaicheng Zhu, Tao Wang, Jiajun Zhang, Hui Cao, Ruichao Shen, Guoqiang Wang, George G. Wu, Yat Sun Or
Antiviral heterocyclic compounds
Patent number: 12006326
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: August 24, 2022
Date of Patent: June 11, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
June 11, 2024
Enanta Pharmaceuticals gets grant for macrocyclic compounds inhibiting coronavirus replication
....the patent outlines methods for treating viral infections, particularly coronavirus infections, by administering the disclosed compound. The methods include oral, subcutaneous, intravenous, or inhalation administration of the compound. Additionally, the patent covers inhibiting viral 3C protease or viral 3CL protease in a subject by administering the compound. The patent specifies the treatment of various strains of coronaviruses, including 229E, NL63, OC43, HKU1, SARS-CoV, and MERS coronavirus, highlighting the broad spectrum of antiviral activity claimed in the patent.
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-macrocyclic-compounds-inhibiting-coronavirus-replication/
Management has already stated such. However, it's still positive to see the following in print -
The company has now completed a majority of its multi-year payer contracts at significantly higher margins to COLL. To underscore this development and what the market is missing, if COLL were to run its business as-is and retire its debt, we estimate it could have a $1 billion net cash position by 2027. Furthermore, if their largest potential competitor (Teva Pharmaceuticals) stays out of the market, it could produce another $1 billion of free cash flow over the next three years. The current market capitalization is roughly $1 billion…”
https://finance.yahoo.com/news/collegium-pharmaceutical-inc-nasdaq-coll-211603220.html
Jefferies upgrades Collegium to buy, cites upside related to LOEs -
Jun. 07, 2024 12:13 PM ET
Jefferies upgraded Collegium (NASDAQ:COLL) to buy, stating it believes the upside potential related to upcoming losses of market exclusivity for Collegium's drugs Nucynta and Belbuca is underappreciated.
The investment bank said it sees several drivers for the drugs despite the LOEs, including a Nucynta partnership with Hikma, pediatric extensions for Nucynta, and uncertainty about Teva's launch of a generic version of Belbuca. It also believes 2024 EBITDA consensus is “too low.”
Jeffries also noted that the company’s cash generation was “significant,” with its net cash expected to eclipse its market cap in fiscal 2028. It added that the company “could likely take itself private in the 2028 timeframe.”
Jefferies set its price target for the stock at $44.
https://seekingalpha.com/news/4114181-jefferies-upgrades-collegium-to-buy-cites-upside-related-to-loes?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain
Jefferies upgrades Collegium to buy, cites upside related to LOEs -
Jun. 07, 2024 12:13 PM ET
Jefferies upgraded Collegium (NASDAQ:COLL) to buy, stating it believes the upside potential related to upcoming losses of market exclusivity for Collegium's drugs Nucynta and Belbuca is underappreciated.
The investment bank said it sees several drivers for the drugs despite the LOEs, including a Nucynta partnership with Hikma, pediatric extensions for Nucynta, and uncertainty about Teva's launch of a generic version of Belbuca. It also believes 2024 EBITDA consensus is “too low.”
Jeffries also noted that the company’s cash generation was “significant,” with its net cash expected to eclipse its market cap in fiscal 2028. It added that the company “could likely take itself private in the 2028 timeframe.”
Jefferies set its price target for the stock at $44.
https://seekingalpha.com/news/4114181-jefferies-upgrades-collegium-to-buy-cites-upside-related-to-loes?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain
Summary judgment hearing for whom?
Explanation needed. T.I.A.
Docket last updated: 10 hours ago
Thursday, June 06, 2024 Notice Setting or Resetting Hearing on Motion Thu 06/06 11:17 AM
ELECTRONIC NOTICE Resetting Daubert and Motion for Summary Judgment Hearing. Motion Hearing set for 7/31/2024 10:00 AM in Courtroom 11 (In person only) before Judge Denise J. Casper.
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
JEFFERIES raises COLL to a BUY from HOLD with a price target - $44.
Since Joe Ciaffoni was terminated, he has been selling his large holdings piecemeal. As a result, the share price is going SOUTH. Obviously, he wants to get revenge & sink the shareholders.
Resolution - B.O.D. - don't vest the upcoming, new President et al with as many perks!!
Another quick move by the B.O.D. - use some of $115M (left out of $150M) to purchase J.C's COLL securities.
On a similar note, I had successful cryoablation for a kidney tumor recently. Originally, my urologist advised me to have a robotic arm remove the entire kidney due to its proximity to my diaphragm. He also gave me an option to discuss such with one of four INTERVENTIONAL RADIOLOGISTS at a local hospital.
Procedure - After a fruitless 2 hours on my stomach, the I.V. turned me a notch & was able to reach, freeze/kill the cancerous cyst. Miraculously, two days later, I was driving! Friends who had the entire kidney removed are still not up to par.
Please contact me if I can help anyone.
Anyone have access to this full article dated May 29, 2024?
Pfizer, Enanta Launch Dueling Bids to Gut Paxlovid Patent Case
https://news.bloomberglaw.com/health-law-and-business/pfizer-enanta-launch-dueling-bids-to-gut-paxlovid-patent-case
Collegium to Participate in Jefferies Global Healthcare Conference
May 29, 2024
STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY from June 5-6, 2024.
Details of the event are as follows:
Fireside Chat Date and Time: Wednesday, June 5, 2024, at 9:30 a.m. ET
The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-participate-jefferies-global-healthcare-conference
Do these patents really matter? (Contrary to my earlier post! )
Saturated spirocyclics as antiviral agents
Patent number: 11993600
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: December 6, 2022
Date of Patent: May 28, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Joseph D. Panarese, Samuel Bartlett, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
May 29, 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY.
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-participate-jefferies-global-healthcare-0
FWIW - Good news for a potential buyer?
Enanta Pharmaceuticals sees highest patent filings and grants during February in Q1 2024
Excerpts:
Enanta Pharmaceuticals saw the highest growth of 199% in patent filings in February and 499% in grants in January in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 24% and grants by 499%.
Patents related to rare diseases and Covid-19 lead Enanta Pharmaceuticals's portfolio
Enanta Pharmaceuticals has the highest number of patents in rare diseases followed by, Covid-19 and climate change. For rare diseases, nearly 50% of patents were filed and 38% of patents were granted in Q1 2024.
Respiratory syncytial virus (rsv) infections related patents lead Enanta Pharmaceuticals portfolio followed by cardiovascular disease, and fatty liver disease
Enanta Pharmaceuticals has highest number of patents in respiratory syncytial virus (rsv) infections followed by cardiovascular disease, fatty liver disease, non alcoholic fatty liver disease (nafld), and non-alcoholic steatohepatitis (nash).
Read more:
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-patent-activity/?cf-view
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Earnings Call Transcript
Published on May 14, 2024
https://www.insidermonkey.com/blog/collegium-pharmaceutical-inc-nasdaqcoll-q1-2024-earnings-call-transcript-1303222/
Collegium Announces $35 Million Accelerated Share Repurchase Program
May 13, 2024
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $115 million remaining under the program.
“Our financial and strategic execution bolster the strength of our business today and in the future. Collegium’s strong start to 2024 was supported by robust cash generation, momentum in Belbuca® prescriptions, improved Xtampza® ER gross-to-net and the Nucynta Franchise authorized generic agreement, all of which put us on track to meet our 2024 financial guidance and improve our outlook in 2025 and beyond,” said Colleen Tupper, Chief Financial Officer of Collegium. “This $35 million ASR program reinforces our belief that the value of Collegium is underappreciated. We remain committed to leveraging our $150 million share repurchase program, which is authorized through the second quarter of 2025, to create value for our shareholders through our capital deployment strategy.”
Under terms of the agreement, Collegium will pay $35 million to Jefferies LLC and will receive an initial delivery of 888,889 shares, based on the $31.50 closing stock price of Collegium’s common stock on May 10, 2024, representing approximately 80% of the total shares the Company expects to repurchase under the ASR agreement. The final number of shares repurchased will be based on the volume-weighted average prices of Collegium’s common stock during the term of the ASR and subject to adjustments related to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed in the third quarter of 2024. As of March 31, 2024, Collegium had approximately 32.7 million shares outstanding.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-35-million-accelerated-share-repurchase
Collegium Announces $35 Million Accelerated Share Repurchase Program
May 13, 2024
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $115 million remaining under the program.
“Our financial and strategic execution bolster the strength of our business today and in the future. Collegium’s strong start to 2024 was supported by robust cash generation, momentum in Belbuca® prescriptions, improved Xtampza® ER gross-to-net and the Nucynta Franchise authorized generic agreement, all of which put us on track to meet our 2024 financial guidance and improve our outlook in 2025 and beyond,” said Colleen Tupper, Chief Financial Officer of Collegium. “This $35 million ASR program reinforces our belief that the value of Collegium is underappreciated. We remain committed to leveraging our $150 million share repurchase program, which is authorized through the second quarter of 2025, to create value for our shareholders through our capital deployment strategy.”
Under terms of the agreement, Collegium will pay $35 million to Jefferies LLC and will receive an initial delivery of 888,889 shares, based on the $31.50 closing stock price of Collegium’s common stock on May 10, 2024, representing approximately 80% of the total shares the Company expects to repurchase under the ASR agreement. The final number of shares repurchased will be based on the volume-weighted average prices of Collegium’s common stock during the term of the ASR and subject to adjustments related to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed in the third quarter of 2024. As of March 31, 2024, Collegium had approximately 32.7 million shares outstanding.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-35-million-accelerated-share-repurchase
FWIW - 5/10
Before the 6 point drop -
We believe that there continues to be a disconnect between the intrinsic value of the company and our share price, which enables us to continue to opportunistically return value to our shareholders by leveraging our share repurchase program. Colleen Tupper - 1stQ CC
https://za.investing.com/news/earnings-call-collegium-pharmaceutical-projects-robust-growth-in-2024-93CH-3141800
In-fighting, disagreements, personality clashes - totally not predicted - who knows??
Joe has my vote.
Need Comments.
Collegium Announces CEO Transition
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-ceo-transition
INVESTOR PRESENTATION SLIDES -
https://ir.collegiumpharma.com/static-files/256cf28c-c774-44b0-82b5-e46427a28463
Excellent -
Collegium Reports First Quarter 2024 Financial Results
May 9, 2024
– Generated Q1’24 Net Revenue of $144.9 Million –
– Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year –
– Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million –
– Delivered Q1’24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year –
– Board of Directors Authorized $35.0 Million Accelerated Share Repurchase Program –
– Reaffirmed Full-Year 2024 Guidance –
Joe C. to step down as President & C.E.O. -
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-first-quarter-2024-financial-results
Patent Assigned to Enanta Pharmaceuticals, Inc.
Spiropyrrolidine derived antiviral agents
Patent number: 11976084
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: November 22, 2021
Date of Patent: May 7, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Ruichao Shen, Jun Ma, Yong He, Xuechao Xing, Hui Cao, Xuri Gao, Xiaowen Peng, Joseph D. Panarese, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
What are the benefits of pyrrolidine?
Pyrrolidines are very important nitrogen-containing heterocycles. It has glucosidase inhibitory activity, along with antiviral, antibacterial, antidiabetic, and anticancer activities.
Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), reducing the price target to $27.00.
Ed Arce has given his Buy rating due to a combination of factors, including Enanta Pharmaceuticals’ promising developments in its RSV (respiratory syncytial virus) franchise. The anticipation of top-line data readouts from two key Phase 2 studies of their lead RSV program, zelicapavir, in the second half of 2024 is a significant driver. The enrollment progress in these studies, especially with one part fully enrolled and the other advancing, reflects positively on the company’s ability to execute its clinical trials. The high potential of zelicapavir in at-risk populations, including children and adults with RSV complications, underscores the market opportunity for Enanta’s product.
Additionally, the upcoming data from a Phase 2a challenge study of EDP-323, another oral RSV candidate with a different mechanism, enhances the company’s RSV pipeline strength. This candidate’s potential efficacy in combination with other RSV therapeutics offers a strategic advantage. Arce also considers the progress in Enanta’s immunology program, particularly the KIT inhibitor candidate for chronic spontaneous urticaria (CSU), which the company expects to select for clinical development by the fourth quarter of 2024. The innovative approach targeting the depletion of mast cells to treat CSU could address a significant unmet medical need, further justifying the positive outlook on Enanta’s stock.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $22.00 price target.
https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-enanta-pharmaceuticals-amidst-promising-rsv-developments-and-clinical-trial-execution?utm_source=moomoo.com&utm_medium=referral&global_content={%22promote_id%22:13764,%22sub_promote_id%22:57}
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--May 7, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 14, 2024 at 10:00 a.m. ET in New York, NY.
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-participate-jmp-securities-life-sciences
Latest Patents Assigned to Enanta Pharmaceuticals, Inc.
Macrocyclic antiviral agents
Patent number: 11970502
Abstract: The present invention discloses macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: May 3, 2022
Date of Patent: April 30, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Jiajun Zhang, Xiaowen Peng, Yat Sun Or
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
Patent number: 11958879
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Type: Grant
Filed: May 19, 2021
Date of Patent: April 16, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
Enanta Pharmaceuticals (from X)
Our team presented “Efficacy and Safety of EDP-235 in Non-hospitalized Adults With Mild or Moderate COVID-19: Results From the Phase 2 SPRINT Study” at
@ESCMID Global where it was named a “Top Rated Poster.” Congratulations to the team.
POSTER CONCLUSIONS
• EDP-235 treatment in standard-risk adults with mild or moderate COVID-19 yielded a favorable safety profile and improvements in clinical symptoms
• EDP-235 was generally well tolerated, as reflected by a low frequency of TEAEs that were mostly mild in severity, and there were no serious TEAEs or
TEAE-related discontinuations
• The 400 mg dose of EDP-235 achieved statistically significant improvement in TSS at multiple time points in the overall study population
– In participants enrolled within 3 days of symptom onset, along with significant TSS improvement at all time points, a median 2-day shorter
duration of 6 selected COVID-19 symptoms was observed
• The rapid decline of viral load across all study groups was consistent with an enrolled population that had prior immunity
• The results of the Phase 2 SPRINT study support further development of EDP-235 for the treatment of COVID-19
• As the therapeutic target is conserved across variants, EDP-235 may prove an effective tool to combat future variants of SAR-CoV-2 and potentially
other coronaviruses
Read more:
https://www.enanta.com/wp-content/uploads/2024/04/P0423_ECCMID_2024_SPRINT_Poster_FINAL.pdf
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
Apr 30, 2024
“I’m pleased to welcome Matt to Enanta. The breadth of his legal expertise across a wide range of activities in the life sciences industry, including his experience with early and late-stage clinical trials, commercial products, intellectual property, business development and other corporate transactions, makes him an important addition to the Enanta leadership team as we advance toward several important catalysts this year,” commented Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. “In addition to his strong expertise and experience, Matt is a proven leader in life sciences, which will support our continued growth as we further our mission of developing important medicines in virology and immunology.”
“I’m proud to join a team with an established track record of success, dedicated to the discovery and development of groundbreaking small molecule drugs in areas of significant unmet medical need,” said Matthew Kowalsky. “With multiple near-term catalysts across the pipeline and a solid cash position, this is an important and transformational time for Enanta. I look forward to collaborating with the seasoned management team to support all initiatives aimed at progressing our pipeline, improving the lives of patients and their caregivers, and enhancing shareholder value.”
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-appointment-matthew-p-kowalsky
Furthermore -
the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta’s new Chief Legal Officer, consisting of a non-qualified stock option to purchase 150,000 shares of its common stock, performance share units (PSUs) for 4,468 shares of its common stock, and relative total stockholder return units (rTSRUs) for 4,468 shares of its common stock, under the company’s 2024 Inducement Stock Incentive Plan.
The 2024 Inducement Stock Incentive Plan has been adopted by the Board of Directors to be used exclusively for the grant of equity awards to any individual who was not previously an employee or non-employee director of Enanta Pharmaceuticals, as an inducement material to such individual's entering into employment with Enanta Pharmaceuticals, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
Read more:
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-inducement-grants-under-nasdaq
Monday, April 29, 2024 8:11:29 AM
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
April 29, 2024
STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta® ER (“the Nucynta Franchise”) in the United States.
“Our agreement with Hikma bolsters the value of the Nucynta Franchise through 2025 and beyond,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “Collegium is pleased to work with Hikma, an industry leader, to ensure that these important products continue to be manufactured to the highest quality standards and remain broadly and consistently accessible to appropriate patients.”
Under the terms of the agreement:
Collegium will manufacture and supply Hikma with all authorized generic product for sale on an exclusive basis during the term of the agreement.
Hikma will sell the authorized generic forms of the Nucynta Franchise in the United States, commencing 30 days prior to the anticipated loss of exclusivity for each product, or earlier under certain circumstances.
Collegium will receive a meaningful share of net profits of the authorized generic products, that declines based on the number of generic entrants, if any. [NO TEVA, HOPEFULLY.(My emphasis.)]
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-authorized-generic-agreement-hikma
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
April 29, 2024
STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta® ER (“the Nucynta Franchise”) in the United States.
“Our agreement with Hikma bolsters the value of the Nucynta Franchise through 2025 and beyond,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “Collegium is pleased to work with Hikma, an industry leader, to ensure that these important products continue to be manufactured to the highest quality standards and remain broadly and consistently accessible to appropriate patients.”
Under the terms of the agreement:
Collegium will manufacture and supply Hikma with all authorized generic product for sale on an exclusive basis during the term of the agreement.
Hikma will sell the authorized generic forms of the Nucynta Franchise in the United States, commencing 30 days prior to the anticipated loss of exclusivity for each product, or earlier under certain circumstances.
Collegium will receive a meaningful share of net profits of the authorized generic products, that declines based on the number of generic entrants, if any. [NO TEVA, HOPEFULLY.]
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-authorized-generic-agreement-hikma
Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
Apr 29, 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-host-conference-call-may-6-430-pm-et